Shandong Xinhua Pharmaceutical Co Ltd (000756) - Cash Flow Conversion Efficiency

Latest as of September 2023: 0.012x

Based on the latest financial reports, Shandong Xinhua Pharmaceutical Co Ltd (000756) has a cash flow conversion efficiency ratio of 0.012x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥56.11 Million ≈ $8.21 Million USD) by net assets (CN¥4.70 Billion ≈ $687.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Shandong Xinhua Pharmaceutical Co Ltd (000756) market capitalisation for the company's overall valuation and market capitalisation.

Shandong Xinhua Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)

This chart illustrates how Shandong Xinhua Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Shandong Xinhua Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Shandong Xinhua Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Explore 000756 operating cash flow to net income to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
CHERVON HOLDINGS LTD
F:AZ9
N/A
Tyntek Corp
TW:2426
0.005x
Shandong Bohui Paper Industry Co Ltd
SHG:600966
0.177x
FAWER Automotive Parts Ltd Co
SHE:000030
0.027x
Guangxi Wuzhou Communications Co Ltd
SHG:600368
0.038x
ArcherMind Technology Nanjing Co Ltd
SHE:300598
0.008x
Wereldhave NV
AS:WHA
0.041x
Metalurgica Gerdau S.A
SA:GOAU3
0.027x

Annual Cash Flow Conversion Efficiency for Shandong Xinhua Pharmaceutical Co Ltd (2015–2024)

The table below shows the annual cash flow conversion efficiency of Shandong Xinhua Pharmaceutical Co Ltd from 2015 to 2024. View 000756 share price today for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥5.22 Billion
≈ $763.48 Million
CN¥367.61 Million
≈ $53.79 Million
0.070x +26.84%
2023-12-31 CN¥4.78 Billion
≈ $698.84 Million
CN¥265.28 Million
≈ $38.82 Million
0.056x -68.13%
2022-12-31 CN¥4.35 Billion
≈ $636.53 Million
CN¥758.24 Million
≈ $110.95 Million
0.174x +145.62%
2021-12-31 CN¥3.65 Billion
≈ $534.28 Million
CN¥259.12 Million
≈ $37.92 Million
0.071x -42.72%
2020-12-31 CN¥3.39 Billion
≈ $496.25 Million
CN¥420.19 Million
≈ $61.49 Million
0.124x +10.66%
2019-12-31 CN¥3.11 Billion
≈ $455.17 Million
CN¥348.27 Million
≈ $50.96 Million
0.112x -3.33%
2018-12-31 CN¥2.80 Billion
≈ $409.22 Million
CN¥323.91 Million
≈ $47.40 Million
0.116x -23.39%
2017-12-31 CN¥2.58 Billion
≈ $377.46 Million
CN¥389.97 Million
≈ $57.07 Million
0.151x -28.45%
2016-12-31 CN¥2.08 Billion
≈ $304.27 Million
CN¥439.35 Million
≈ $64.29 Million
0.211x +20.25%
2015-12-31 CN¥1.98 Billion
≈ $290.33 Million
CN¥348.64 Million
≈ $51.02 Million
0.176x --

About Shandong Xinhua Pharmaceutical Co Ltd

SHE:000756 China Drug Manufacturers - Specialty & Generic
Market Cap
$965.83 Million
CN¥6.60 Billion CNY
Market Cap Rank
#9119 Global
#2258 in China
Share Price
CN¥13.34
Change (1 day)
+4.55%
52-Week Range
CN¥11.95 - CN¥18.15
All Time High
CN¥44.80
About

Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. It offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for act… Read more